Stock Track | LifeTech Scientific Soars 5.36% Intraday on Strong 2025 Annual Results with Adjusted Net Profit Up 24.9%

Stock Track

Apr 01

LifeTech Scientific Corporation's stock surged 5.36% during intraday trading on Wednesday, following the release of its robust annual financial results for 2025.

The medical device company reported steady revenue growth of approximately 5.1% year-on-year to RMB1,369.8 million, driven by a 19.9% increase in stent graft sales. Notably, the company's adjusted net profit saw a significant increase of approximately 24.9% to RMB353.4 million, while its gross profit margin remained strong at 74.4%.

The positive performance was supported by considerable growth in overseas markets, particularly in Europe where sales grew by approximately 25.9%, making it the Group's largest overseas market. The company also maintained a strong cash position and continued its commitment to innovation, with R&D investment accounting for about 24.0% of total revenue.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1188582728"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188582728\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188582728?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188582728","market":"nz","top_or_hot":-1,"title":"Stock Track | LifeTech Scientific Soars 5.36% Intraday on Strong 2025 Annual Results with Adjusted Net Profit Up 24.9%","media":"Stock Track","content":"<p>LifeTech Scientific Corporation's stock surged 5.36% during intraday trading on Wednesday, following the release of its robust annual financial results for 2025.</p><p>The medical device company reported steady revenue growth of approximately 5.1% year-on-year to RMB1,369.8 million, driven by a 19.9% increase in stent graft sales. Notably, the company's adjusted net profit saw a significant increase of approximately 24.9% to RMB353.4 million, while its gross profit margin remained strong at 74.4%.</p><p>The positive performance was supported by considerable growth in overseas markets, particularly in Europe where sales grew by approximately 25.9%, making it the Group's largest overseas market. The company also maintained a strong cash position and continued its commitment to innovation, with R&D investment accounting for about 24.0% of total revenue.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | LifeTech Scientific Soars 5.36% Intraday on Strong 2025 Annual Results with Adjusted Net Profit Up 24.9%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | LifeTech Scientific Soars 5.36% Intraday on Strong 2025 Annual Results with Adjusted Net Profit Up 24.9%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-01 10:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LifeTech Scientific Corporation's stock surged 5.36% during intraday trading on Wednesday, following the release of its robust annual financial results for 2025.</p><p>The medical device company reported steady revenue growth of approximately 5.1% year-on-year to RMB1,369.8 million, driven by a 19.9% increase in stent graft sales. Notably, the company's adjusted net profit saw a significant increase of approximately 24.9% to RMB353.4 million, while its gross profit margin remained strong at 74.4%.</p><p>The positive performance was supported by considerable growth in overseas markets, particularly in Europe where sales grew by approximately 25.9%, making it the Group's largest overseas market. The company also maintained a strong cash position and continued its commitment to innovation, with R&D investment accounting for about 24.0% of total revenue.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01302","symbol_name":"先健科技","start_time":0,"source_url":"","article_id":"1188582728","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188582728","pubTimestamp":1775011190,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"LifeTech Scientific Corporation's stock surged 5.36% during intraday trading on Wednesday, following the release of its robust annual financial results for 2025.The medical device company reported...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01302":"先健科技"},"translate_title":"个股赛道|先健科技2025年度业绩强劲盘中大涨5.36%经调整净利润升24.9%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01302":1},"content_text":"LifeTech Scientific Corporation's stock surged 5.36% during intraday trading on Wednesday, following the release of its robust annual financial results for 2025.The medical device company reported steady revenue growth of approximately 5.1% year-on-year to RMB1,369.8 million, driven by a 19.9% increase in stent graft sales. Notably, the company's adjusted net profit saw a significant increase of approximately 24.9% to RMB353.4 million, while its gross profit margin remained strong at 74.4%.The positive performance was supported by considerable growth in overseas markets, particularly in Europe where sales grew by approximately 25.9%, making it the Group's largest overseas market. The company also maintained a strong cash position and continued its commitment to innovation, with R&D investment accounting for about 24.0% of total revenue.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}